Lv6
1717 积分 2024-05-13 加入
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
7天前
已完结
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia
17天前
已完结
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia
23天前
已完结
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
28天前
已完结
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
28天前
已完结
Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France
1个月前
已完结
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
1个月前
已完结
Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)
1个月前
已完结
Updating Efficacy of First‐Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab
1个月前
已完结
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study
1个月前
已完结
皖公网安备34019202002308
